ISSN: 1300-7777 E-ISSN: 1308-5263
Acute Monoblastic Leukemia as a Second Malignancy After Doxorubicin and Cisplatin Treatment for Osteosarcoma [Turk J Hematol]
Turk J Hematol. 2003; 20(1): 39-42

Acute Monoblastic Leukemia as a Second Malignancy After Doxorubicin and Cisplatin Treatment for Osteosarcoma

Sinan Mahir Kayıran, Namık Özbek
Department Of Pediatrics, Başkent University Faculty Of Medicine, Ankara, Turkey

Secondary or therapy-related acute myeloid leukemia (t-AML) occurs as a complication of various chemotherapy regimens. In pediatric age group, leukemia as a second malignancy after osteosarcoma treatment with doxorubicin and cisplatin is relatively rare. A 15-year-old girl was admitted to our hospital with signs and symptoms of leukemia. She had been treated one-year earlier with doxorubicin and cisplatin for osteosarcoma of the left femur. The patient was diagnosed with acute monoblastic leukemia on the basis of bone marrow examination and immunophenotype analysis. There were no cytogenetic abnormalities. The patient’s father had been diagnosed with pelvic chondrosarcoma, which suggested a familial susceptibility to cancer. We interpreted this as a rare case of t- AML with normal cytogenetic analysis, and believe the disease was induced by the addition of platinum compounds to a regimen including topoisomerase II inhibitors.

Keywords: Therapy-related leukemia, Cisplatin, Doxorubicin, Osteosarcoma.


Doksorubisin ve Sisplatinle Osteosarkom Tedavisi Ardından İkincil Malignite Olarak Gelişen Akut Monoblastik Lösemi

Sinan Mahir Kayıran, Namık Özbek
Department Of Pediatrics, Başkent University Faculty Of Medicine, Ankara, Turkiye

Sekonder ya da tedaviye bağlı AML (t-AML) çeşitli kemoterapi rejimlerinin komplikasyonu olarak ortaya çıkar. Pediatrik yaş grubunda osteosarkom tedavisine sekonder malignite nadirdir. Onbeş yaşında bir kız çocuğu hastanemize akut lösemi yakınma ve bulguları ile başvurdu. Bir yıl öncesi sol femur osteosarkom tanısı ile doksorubisin ve sisplatin alan hastaya kemik iliği incelemesi ve immünfenotiplendirme ile akut monoblastik lösemi tanısı kondu. Sitogenetik anomali saptanmadı. Hastanın babası pelvik kondrosarkoma tanısı almış olup, ailesel yatkınlık düşünüldü. Biz bu olguyu sitogenetik anomalisi olmayan nadir bir t-AML olgusu olarak değerlendirdik ve nedeninin topoizomeraz II inhibitörleri içeren bir rejime platinum bileşikleri eklenmesi olduğuna inanmaktayız.

Anahtar Kelimeler: Tedaviye bað, lı lösemi, Sisplatin, Doksorubisin, Osteosarkom.


Sinan Mahir Kayıran, Namık Özbek. Acute Monoblastic Leukemia as a Second Malignancy After Doxorubicin and Cisplatin Treatment for Osteosarcoma. Turk J Hematol. 2003; 20(1): 39-42

Corresponding Author: Sinan Mahir Kayıran, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2017) = 0.650